CONVERGE Post-Approval Study (PAS)
← catalyst calendarNCT05393180 · readout in 134 d
Sponsored by AtriCure, Inc. (industry) · ATRC — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
53actual
Sites
13
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-04-13 | actual | When the study began enrolling |
| Primary completion | 2027-01-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-21 | estimated | The whole study's end, after follow-up |
| First posted | 2022-05-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Atrial Fibrillation
Intervention
- Device: Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF
Primary outcomes
what the primary-completion date above is the date OFFreedom from AF/AFL/AT >30 seconds through 12 months absent new or increased dose of class I/III AAD.
measured 1 year
Primary Safety Endpoint, Incidence of defined Major Adverse Events
measured 30-days post procedure
Permalink · ATRC's whole pipeline · Catalyst calendar · Every registered study · What changed